US Patent

US11618733 — Crystalline salts of a plasma kallikrein inhibitor

Method of Use · Assigned to Biocryst Pharmaceuticals Inc · Expires 2039-11-01 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects crystalline salts of a plasma kallikrein inhibitor, methods of preparing them, and related pharmaceutical preparations for treatment.

USPTO Abstract

Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3300`	—
`U-3300`	—

Patent Metadata

Patent number: US11618733
Jurisdiction: US
Classification: Method of Use
Expires: 2039-11-01
Drug substance claim: No
Drug product claim: No
Assignee: Biocryst Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.